Papalocal
Loading…
News
← All news
Health

CAR-T therapy shows dramatic early results for stiff person syndrome, the disease affecting Céline Dion

A Mayo Clinic trial published in JAMA Neurology found that some patients who could barely walk regained the ability to work and resume hobbies — a level of recovery rarely seen with existing treatments.

How does this story make you feel?

For years, doctors treating stiff person syndrome have had one realistic goal: slow the damage. A small clinical trial published in JAMA Neurology suggests a different outcome may now be possible — patients who previously needed family members to help them walk have returned to work, gone hunting and fishing, and cried on a treadmill after managing seven minutes at a pace they feared they would never reach again.

The treatment is CAR-T cell therapy, already established in cancer care, and now being trialled at the Mayo Clinic in Rochester for stiff person syndrome (SPS) — the rare autoimmune neurological disorder that Céline Dion announced she had been diagnosed with in December 2022. Researchers extracted patients' own T cells, a type of immune cell, engineered them to target and wipe out disease-causing cells, and administered the therapy as a one-time treatment.

What was most striking was the degree of improvement we saw in some patients. With existing treatments, we may be able to improve symptoms but we very rarely see patients return to their previous level of function. These early results are very encouraging and the key question now is whether those improvements will be sustained over time.— Dr. Anastasia Zekeridou, neurologist and researcher, Mayo Clinic

That distinction — returning to a previous level of function, not merely reducing symptoms — is what separates these findings from the standard of care. Current first-line treatments for SPS include muscle relaxants, benzodiazepines, intravenous immunoglobulin (IVIG), and physical therapy. According to Dr. Leah Croll, an assistant professor of neurology at the Lewis Katz School of Medicine at Temple University, those therapies are designed to lessen the severity of symptoms or potentially slow progression, but none specifically targets the disease itself.

I can go to work every single day. I can do everything I did before. I go hunting; I can go fishing. I have not had one episode since receiving treatment.— Jonathan Walden, trial participant

Another patient, Shari St Germain, had experienced severe leg cramps, difficulty walking, muscle rigidity and falls before the trial. After CAR-T treatment, she described walking on a treadmill for seven minutes — an act that moved her to tears and brought her husband running to check on her.

After the treatment, I got up one day and I'm like 'I'm feeling really good', and I went to walk on the treadmill. My husband comes running in because I'm crying and he's like: 'Are you OK?' And I'm like: 'I just walked for seven minutes on the treadmill'.— Shari St Germain, trial participant

The implications, researchers say, could extend beyond SPS. Dr. Sean Pittock, chair of the department of neurology at Mayo Clinic, pointed to the broader class of immune-mediated neurological conditions where effective options remain limited.

CAR-T therapy has already transformed the treatment of some cancers, and we are now beginning to see its potential in autoimmune neurologic diseases. The results in stiff person syndrome offer tremendous hope, not only for people living with this disease but potentially for patients with other immune-mediated neurologic conditions where effective treatment options remain limited. There is still much we need to learn but this opens an exciting new avenue for the field.— Dr. Sean Pittock, chair of neurology, Mayo Clinic

Stiff person syndrome is a progressive neurological disorder with autoimmune features that affects roughly one to two people per million, according to Johns Hopkins Medicine. It causes muscle stiffness in the torso and limbs, and a heightened sensitivity to noise, touch and emotional stress that can trigger painful spasms. People with the condition may develop a hunched posture, struggle to walk, and fall more frequently because they lack the muscle reflexes to catch themselves. It affects women at roughly twice the rate of men, according to the National Institutes of Health. There is no cure.

Dion, 58, is not reported to have received the experimental CAR-T therapy. She has been managing her condition through her established treatment regimen and has returned to performing. She kicked off a 26-show run at the Plenitude Arena in Nanterre, France, on September 12, her first concert in six years, performing to a sold-out crowd of 30,000. She is scheduled to perform until mid-October before resuming in May 2027, according to ABC News.

I had promised myself not to cry. But I'm so happy to see you all. I missed you.— Céline Dion, performing at Plenitude Arena, September 12

Dion had announced her diagnosis in December 2022, saying in a taped video that the condition had affected "every aspect of my daily life," including her ability to use her vocal cords. She canceled all upcoming performances at the time. In 2024, she released a documentary, "I Am: Céline Dion," on Prime Video, and made a brief return to the stage at the Paris Olympics opening ceremony, singing "L'Hymne à L'Amour." On her birthday in March 2026, she announced the Paris concert run, describing it as "the best gift of my life."

I'm doing great, managing my health. I'm feeling good. I'm singing again, even doing a little bit of dancing.— Céline Dion, social media video, March 30, 2026

Dion's physician, Dr. Amanda Piquet, told TODAY's Hoda Kotb in mid-2024 that Dion had made "significant progress" with her treatment since the documentary was filmed. Dion herself said she knew some performances might still need to be called off, but was clear she would not allow the disease to control her life.

Outside observers welcomed the Mayo Clinic findings. Yasmin Sheikh, head of policy and public affairs at Anthony Nolan, a blood cancer charity not involved in the trial, said the research provided "more evidence that CAR-T cell therapies could have applications beyond blood cancer and offer new hope to people living with other conditions, including SPS," according to The Guardian. Researchers themselves were careful to note the results are preliminary and that the central question — whether improvements will last — remains unanswered. Larger trials will be needed before the therapy could become a standard option.

Why it matters — For the roughly one to two people per million living with stiff person syndrome — a disease with no cure and treatments that rarely restore function — CAR-T cell therapy represents the first documented path back to something resembling a normal life, though larger trials are still needed to confirm whether the results hold.

⚠ Not yet confirmed

  • The CAR-T trial involved only a small number of patients; the exact number is not specified in the available sources.
  • specific publication date November 9, 2026

Reported by usatoday.com, telegraph.co.uk, cbc.ca, today.com, theguardian.com, abcnews.com

People in this story

Community

Be the first to comment.

Share this story
Text Email